The MDM2 (Mouse Double Minute 2 Homolog) antibody is a critical tool in cancer research and molecular biology, primarily targeting the MDM2 protein, a key regulator of the tumor suppressor p53. MDM2 functions as an E3 ubiquitin ligase, promoting p53 degradation via the proteasome, thereby inhibiting p53-mediated cell cycle arrest and apoptosis. Overexpression of MDM2. often observed in various cancers, disrupts this balance, leading to uncontrolled cell proliferation and tumor progression. MDM2 antibodies are widely used to study protein expression levels, subcellular localization, and interactions in experimental models, employing techniques like Western blotting, immunohistochemistry (IHC), and immunoprecipitation. They also aid in evaluating MDM2 amplification or dysregulation, which correlates with poor prognosis in cancers such as sarcomas, gliomas, and carcinomas. Additionally, MDM2 antibodies are instrumental in developing therapeutic strategies, including small-molecule inhibitors (e.g., Nutlin-3) that block MDM2-p53 interactions to reactivate p53 function. Their role extends to diagnostic applications, such as detecting MDM2 overexpression in tumor samples. Research using MDM2 antibodies continues to unravel its dual role as both an oncogene and a p53 modulator, highlighting its potential as a therapeutic target in precision oncology.